Cytokinetics (NASDAQ:CYTK) Executive Sells Shares Amidst Myqorzo Expansion
An executive at Cytokinetics (NASDAQ:CYTK) sold 3,500 shares for approximately $224,035.00. The company's heart disease treatment, Myqorzo, is expanding its market reach with strong U.S. prescription rates and international approvals. Cytokinetics exhibits a trailing price-to-earnings ratio of…